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ABSTRACT
Fluorescent microscopy experiments show that
when 2’-O-methyl-modified molecular beacons
(MBs) are introduced into NIH/3T3 cells, they elicit a
nonspecific signal in the nucleus. This false-positive
signal can be avoided by conjugating MBs to macro-
molecules (e.g. NeutrAvidin) that prevent nuclear
sequestration, but the presence of a macromolecule
makes efficient cytosolic delivery of these probes
challenging. In this study, we explored various
methods including TAT peptide, Streptolysin O and
microporation for delivering NeutrAvidin-conjugates
into the cytosol of living cells. Surprisingly, all of
these strategies led to entrapment of the conjugates
within lysosomes within 24h. When the conjugates
were pegylated, to help prevent intracellular recog-
nition, only microporation led to a uniform cytosolic
distribution. Microporation also yielded a trans-
fection efficiency of 93% and an average viability of
86%. When cells microporated with MB–NeutrAvidin
conjugates were examined via flow cytometry, the
signal-to-background was found to be more than
3 times higher and the sensitivity nearly five times
higher than unconjugated MBs. Overall, the present
study introduces an improved methodology for
the high-throughput detection of RNA at the single
cell level.
INTRODUCTION
The ability to measure gene expression, using techniques
such as DNA microarrays and reverse transcriptase PCR,
has proven to be invaluable in molecular biology, drug
development and clinical diagnostics. A major limitation
of these approaches, however, is they generally report only
the relative change in gene expression for a population of
cells. In many cases, it is the aberrant RNA expression
of only a small percentage of cells that may be of interest.
Therefore, there is still a need for high-throughput
methods that allow RNA levels to be measured at the
single cell level.
Over the past decade, much eﬀort has been devoted to
developing ﬂuorescent probes that are capable of imaging
RNA at the single-cell level. Of these, perhaps molecular
beacons (MBs) have garnered the most attention. MBs are
antisense oligonucleotide probes labeled with a ‘reporter’
ﬂuorophore at one end and with a quencher at the other
end (1). In the absence of complementary nucleic acid
targets, the MBs assume a stem–loop conﬁguration. As a
result, the ﬂuorophore and quencher are brought into
close proximity and ﬂuorescence is quenched. When MBs
hybridize to complementary targets, the ﬂuorophore is
separated from the quencher and ﬂuorescence is restored.
MBs have already been used to study gene expression in
a variety of live cell applications, ranging from monitoring
the transport and the distribution of b-actin mRNAs
in motile ﬁbroblasts to the detection of speciﬁc RNAs in
living cancer cells (2–13).
Although MBs clearly hold promise as a tool for the
analysis of RNA at the single cell level, we have previously
shown that when nuclease-vulnerable MBs are introduced
into living cells via microinjection, they are quickly
sequestered into the nucleus and generate false-positive
signals (5). Presumably, these false-positive signals arise
when MBs interact with nucleases and/or nucleic acid-
binding proteins. One strategy to overcome nuclear
sequestration involves attaching MBs to macromolecules
such as quantum dots or streptavidin, whereby MB
conjugates cannot pass through the nuclear pores and
are eﬀectively retained in the cytoplasm (2,5). This
eliminates the nonspeciﬁc signal observed in the nucleus.
It is likely that before MB–macromolecular conjugates
become widely adopted as a tool for RNA imaging, stra-
tegies that allow for the eﬃcient delivery of these probes
into the cytosol of living cells must be identiﬁed. Although
microinjection can be used to direct the probes into the
cytosol, this method is tedious, ineﬃcient and impractical
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Alternative delivery methods that have recently been
shown to be eﬀective in delivering unmodiﬁed MBs into
living cells include cell penetrating peptides (CPPs) and
Streptolysin O (SLO), which is a pore-forming bacterial
exotoxin that binds to cell membranes (4,9,14). The speci-
ﬁc CPP used was the 11 amino-acid peptide of the human
immunodeﬁciency virus type I TAT protein. To date, TAT
peptide has been demonstrated to direct the internaliza-
tion of numerous cargoes including small peptides (15),
proteins and polymers (16–18), oligonucleotides including
molecular beacons (9,19), phage vectors (16), liposomes
and polymersomes (20,21) and nanoparticles (22,23).
Internalization of TAT peptide is thought to be through
micropinocytosis although the exact mechanism is still
under debate (24–28). SLO, on the other hand, permea-
bilizes adherent and nonadherent cells by reversibly
forming pores on the cell surface (14,29–34). It has been
shown that SLO can be used to deliver oligonucleotides
(including MBs), dextran and proteins up to 100kDa in
mass into the cytosol (29,30,34). Although not previously
utilized for delivering MBs, electroporation provides yet
another possibility for delivering MB–macromolecular
conjugates into living cells. The transient permeabilization
of the plasma membrane during application of an electric
ﬁeld is a well-established technique for transfecting RNA,
DNA, ﬂuorescent dyes, dextrans, peptides and proteins
into various cell lines (35–39). A common problem often
experienced with electroporation is low cell viability;
however, recent advances in electroporation technology
such as the ability to perform electroporation in microliter
volume spaces (e.g. pipette tips) has led to a reduction in
the many harmful events associated with this process,
including heat generation, metal ion dissolution, pH
variation and oxide formation (www.microporator.com).
This microliter volume electroporation process is known
as microporation (Digital Bio Technology).
In this study, we compared CPPs, SLO and micropo-
ration as methods to deliver NeutrAvidins and MB–
NeutrAvidin conjugates into living cells. NeutrAvidin,
a deglycosylated variant of avidin, was utilized because its
biotin-binding capabilities allows for facile conjugation to
biotinylated MBs, it is of similar size as streptavidin and
thus should prevent nuclear localization of MB con-
jugates, and it reportedly exhibits less nonspeciﬁc interac-
tions than streptavidin (http://probes.invitrogen.com).
Cells microporated with MB–NeutrAvidin conjugates
were further examined via ﬂow cytometry to conﬁrm
MB hybridization with cytoplasmic RNA. The intracel-
lular signal-to-background of MB–NeutrAvidin conju-
gates was also measured and compared with unconjugated
MBs. Overall, this study provides a strategy for the
eﬃcient, high-throughput analysis of speciﬁc RNA
expression in single living cells.
MATERIALS AND METHODS
MB design
Antisense ﬁreﬂy luciferase 20-O-methyl RNA MBs posses-
sing a TEX 613 ﬂuorophore (Ex: 596nm, Em: 613nm)
at the 50 end, an Iowa Black RQ quencher, IBRQ, at the 30
end and a biotin-dT group incorporated in the 30 stem was
synthesized by Integrated DNA Technologies, Inc.
(Coralville, IA, USA). The antisense sequence of ﬁreﬂy
luciferase (pGL3-Luc 235-252, Promega, Madison,
Wisconsin, USA) was chosen because it is not comple-
mentary to any known endogenous RNA target in NIH/
3T3 cells. Speciﬁcally, the antiluciferase MB employed was
TEX613-mGmUmCmAm
CmCmUmCmAmGmCmGmUmAmAmGmUmGmAm
UmGmTmCmG(bio-dT) mGmAmC-IBRQ. A comple-
mentary Luciferase RNA oligonucleotide target was also
synthesized, with the sequence rUrGrGrArCrArUrCrAr
CrUrUrArCrGrCrUrGrArGrUrA.
Synthesis ofNeutrAvidin/MB conjugates
NeutrAvidin (Pierce, Rockford, IL, USA) was dissolved in
50mM Sodium Borate buﬀer, pH 8at a concentration of
10mg/ml and reacted with Cy5-NHS ester (Amersham
Biosciences, Piscataway, NJ, USA) or Alexa750-NHS ester
(Invitrogen, Carlsbad, CA, USA) at dye to NeutrAvidin
molar ratio of 2.5:1. Similarly, an additional sample of
NeutrAvidin was labeled with FITC (Sigma, St. Louis,
MO, USA) at a dye to NeutrAvidin molar ratio of 10:1.
The ﬂuorescent conjugates were puriﬁed on NAP-5 gel
chromatography columns (Amersham Biosciences) in
Phosphate Buﬀer (48mM K2HPO4, 4.5mM KH2PO4,
14mM NaH2PO4), pH 7.2. The number of ﬂuorophores
per NeutrAvidin was determined using a Cary100 spectro-
photometer (Varian). It was determined that there were 3.6
FITC, 1.5 Cy5 and 1.7 Alexa750 per NeutrAvidin,
respectively. Pegylated NeutrAvidin conjugates were
synthesized by further reacting ﬂuorescently labeled
NeutrAvidins with Methyl PEOn-NHS ester (n=8,
Pierce) at various PEG to NeutrAvidin molar ratios
(200:1, 100:1, 50:1 and 25:1), and puriﬁed by repeated
ﬁltration and dilution on Microcon YM-30 centrifugal
devices (30000MW cutoﬀ; Millipore, Billerica, MA,
USA). Initial experiments indicated that when the pegy-
lated NeutrAvidins were microporated into NIH/3T3 cells,
those with 200:1 and 100:1 PEG labeling ratios yielded a
diﬀuse cytoplasmic distribution of NeutrAvidin as deter-
mined by ﬂuorescence microscopy. Microporation and
ﬂuorescence microscopy protocols are described below.
NIH/3T3 cells that were microporated with NeutrAvidin
that was pegylated at a labeling ratio of 50:1 and 25:1
exhibited punctate cytoplasmic ﬂuorescence. As a result, a
100:1 labeling ratio was used for the subsequent studies.
TAT-NeutrAvidin conjugates were synthesized by reacting
ﬂuorescently labeled NeutrAvidins, pegylated and unpe-
gylated, with biotin-TAT (YGRKKRRQRRR-biotin) at a
molar ratio of 4:1 TAT to NeutrAvidin. MB–NeutrAvidin
conjugates were synthesized by reacting ﬂuorescently
labeled NeutrAvidins with biotinylated antisense MBs at
a molar ratio of 1.5:1 MB to NeutrAvidin, prior to
pegylation. All conjugation reactions were allowed to react
overnight at room temperature. All conjugates were
puriﬁed on YM-30 centrifugal devices and concentrations
were determined spectrophotometrically.
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NIH/3T3 cells (ATCC, Manassas, VA, USA) were
cultured in DMEM supplemented with 10% fetal bovine
serum and incubated in 5% CO2 at 378C. To generate cells
that express Fireﬂy luciferase, the NIH/3T3 cells were
infected with adenovirus, H40 040CMVﬀLuciferase
(Penn Genomic Center, Philadelphia, PA, USA), at a
multiplicity of infection of 10
4 particles per cell. Infection
was carried out 24h prior to delivery of NeutrAvidin
conjugates without any apparent loss of viability. Fireﬂy
activity was conﬁrmed by making bioluminescent mea-
surements on a Glomax 20/20 luminometer (Promega)
following the administration of SteadyGlo (Promega).
Microinjection
Microinjection was carried out using a Femtojet and
Injectman NI 2 (Eppendorf, Westbury, NY, USA) micro-
injection system ﬁtted with Femtotips I (Eppendorf). Prior
touse,Femtoptipswere treatedwithHexamethyldisilazane
(Fluka) for 10min, followed by repeated washes in
phosphate buﬀer. Cells were microinjected with samples
containing 2.5 or 10mM antisense 20-O-methyl MBs in
phosphate buﬀer, pH 7.2.
TAT-mediated delivery
NIH/3T3 cells were seeded in 48-well plates in DMEM-
FBS with no antibiotics 1day prior to experimentation
such that they were 50–70% conﬂuent on the second day.
Pegylated and unpegylated TAT-Cy5-NeutrAvidin were
added to the wells at a ﬁnal NeutrAvidin concentration of
200nM in 100ml media. Fusogenic peptides were also
added to the wells at ﬁnal concentrations ranging from 0 to
100mM. The speciﬁc fusogenic peptides tested were INF-7
(GLFEAIEGFIENGWEGMIDGWYG-(PEG)6-NH2),
GALA-INF3 (GLFEAIEGFIENGWEGLAEALAEAL
EALAA-(PEG)6-NH2) and HA2 (GLFGAIAGFIENGW
EGMIDGWYG-(PEG)6-NH2). The (PEG)6 linker was
added to each peptide to increase solubility. All of
the peptides were synthesized by Biopeptide Co., Inc.,
San Diego, CA, USA. Fluorescent images of the cells were
acquired over the course of 24h as described below.
SLO delivery
The method used to delivery MB conjugates into NIH/
3T3 cells by reversible membrane permeabilization with
SLO was modiﬁed from previously established methods
described by Walev et al. (29) and Faria et al. (34). Brieﬂy,
110U of SLO (Sigma) was activated in 100ml of PBS
containing 5mM dithiothreitol (Pierce) and 0.05% BSA
for 2h at 378C. NIH/3T3 cells plated in 48-well plates
were washed once with PBS and were incubated in 100ml
of HBSS containing 30mM HEPES, pH 7.2 for 20min at
378C. NeutrAvidin (5, 15, 25 or 50ml) and an optimized
amount (50ml) of activated SLO was then added to the
cells yielding a ﬁnal NeutrAvidin concentration of 0.8, 2.3,
3.6 or 6.25mM, respectively. After incubating the cells for
20min at 378C, 300ml of ice-cold resealing media
(DMEM–FBS containing 2mM Ca
+2) was added to
each well. Cells were then allowed to reseal at 48C for
60min (30). After the resealing step, the media was
replaced with fresh resealing media and images were
acquired at various time points over the course of 24h.
Microporation
Microliter volume electroporation was performed with
a OneDrop MicroPorator (MP-100, BTX Harvard
Apparatus). Speciﬁcally, NIH/3T3 cells were seeded in
48-well plates in DMEM–FBS with no phenol red and no
antibiotics 1day prior to experimentation. The cells were
then trypsinized and suspended in media without phenol
red, washed with 1  PBS, and ﬁnally resuspended in
resuspension buﬀer R (BTX Harvard Apparatus) at a con-
centration of 120000 cells per 11ml. NeutrAvidin conju-
gates (1ml) were added to the cells such that the ﬁnal
concentration of NeutrAvidin was 1, 2 or 3mM probe.
The 10ml of the cells (i.e. 100000 cells) were then micro-
porated at 1250V, 1500V or 1700V with a 10ms pulse
width, 3 pulses total. Following microporation the cells
were either seeded in 24-well plates and imaged at various
time points over the course of 24h or immediately sus-
pended in 1  PBS for ﬂow cytometric analysis.
Lysosomal labeling
Twenty-four hours after the NeutrAvidin conjugates were
delivered into NIH/3T3 cells with CPPs, SLO or micro-
poration, the cells were washed with 1  PBS, and
LysoTracker Green DND-153 (Invitrogen) was added at
a ﬁnal concentration of 1mMi n1   PBS. Cells were
incubated with the LysoTracker loading solution for 2min
and then washed and incubated with fresh PBS. The cells
were immediately imaged via ﬂuorescence microscopy.
Cytotoxicityassay
The eﬀect of microporation voltage and NeutrAvidin
concentration on the viability of NIH/3T3 cells was
assessed via an MTT assay (ATCC) according to the
manufacture’s instructions. To determine the eﬀect of
voltage, cells were microporated at 0, 1250, 1500 or 1740V
in the presence of 3mM FITC-PEG-NeutrAvidin conju-
gates. The number of pulses was kept constant at 3 and
the pulse width was held constant at 10ms. To determine
the eﬀect of NeutrAvidin concentration, cells were micro-
porated at 1740V in the presence of 0, 1, 2 or 3mM
of FITC-PEG-NeutrAvidin conjugates. FITC-labeled,
pegylated NeutrAvidins were used for the MTT assay to
ensure that there was no signiﬁcant spectral overlap
between the FITC absorbance (490nm) and the MTT
absorbance (570nm). Absorbances were measured on a
Cary100 spectrophotometer (Varian). Viability of cells
was determined by dividing the absorbance measurements
of the electroporated cells by the absorbance of cells that
were not electroporated (0V).
Fluorescent imaging
All microscopy images were acquired with an Olympus IX
81 motorized inverted ﬂuorescence microscope equipped
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X-cite 120 excitation source (EXFO) and Sutter excitation
and emission ﬁlter wheels. Images of LysoTracker Green,
Texas Red, Cy5 and Alexa750 were acquired using the
ﬁlter sets (HQ480/40, HQ535/50, Q505LP), (HQ560/55,
HQ645/75, Q595LP), (HQ620/60, HQ700/75, Q660LP)
and (HQ710/75, HQ810/90, Q750LP) (Chroma,
Rockingham, VT 05101), respectively. A LUC PLAN
FLN 40  objective (NA 0.6) was used for all cell imaging
studies. Results were analyzed with NIH Image J.
Flow cytometryanalysis
Transfection efficiency. Following microporation of NIH/
3T3 cells in the presence of FITC-labeled, pegylated
NeutrAvidin conjugates (as described in the Cytotoxicity
assay section), the cells were washed once in PBS and
analyzed on a Guava Excite ﬂow cytometer ﬁtted with
a 488nm excitation laser. Flow cytometry data was analy-
zed with FLOWJO (Version 7.2.2; Tree Star, Ashland, OR,
USA). Fluorescence signal intensity was deﬁned as the
mean intensity of cells lying within a predeﬁned gate. The
appropriate gate was deﬁned on an FSC versus SSC dot
plot of NIH/3T3 cells that were not electroporated (0V).
Luciferase RNA detection. Wild-type or adenovirus-
infected NIH/3T3 cells were microporated at 1740V in
the presence of 700nM MB–NeutrAvidin conjugates
(NeutrAvidin was labeled with Alexa750 and pegylated)
or 700nM unconjugated MBs. The cells were washed in
1  PBS before being analyzed using an LSR II ﬂow
cytometer (Becton Dickinson) equipped with a 532nm
laser, a 600nm long pass dichroic ﬁlter and a 610nm
PE-Texas Red emission ﬁlter (610/20). Flow cytometry
data were analyzed as described above.
RESULTS AND DISCUSSION
2’-O-methyl RNA MBs elicit afalse-positive signal
in thenucleus of livingcells
Previously, we have shown that when nuclease-vulnerable
molecular beacons are introduced into living cells, they are
quickly sequestered into the nucleus and elicit a false-
positive signal (5). To determine whether this was a result
of nucleus degradation and/or nonspeciﬁc interactions,
we investigated whether MBs composed of 2-O0-methyl
RNA backbones, which are generally considered resistant
to nuclease degradation also elicit a false-positive signal in
the nucleus of living cells. Speciﬁcally, we microinjected
antisense luciferase 20-O0-methyl RNA MBs that were not
complementary to any known endogenous RNA into
NIH/3T3 cells. It was hypothesized that these MBs would
remain quenched unless opened due to non-speciﬁc
interactions. Consequently, an increase in ﬂuorescence
would indicate that nonspeciﬁc interactions could cause
false-positive events.
Following cytoplasmic injection of 2-O0-methyl RNA
MBs, there was a gradual increase in ﬂuorescence observed
in the nucleus (Figure 1a). To determine whether the
increaseinsignalwassimplytheresultofMBaccumulation
or nonspeciﬁc opening of MBs, the total ﬂuorescence of the
cell was quantiﬁed over time. It was determined that the
total MB ﬂuorescence increased by  82% over the course
of 30min, which suggests that nonspeciﬁc opening of MBs
was creating false-positive signals. To further explore
whether the increase in ﬂuorescence was in response to
undesirableMBhybridizationorduetononspeciﬁcprotein
interactions, live cell competitive inhibitions studies were
performed. Speciﬁcally, a 10-fold excess of unlabeled
20-O-methyl RNAs with the same targeting sequence as
the MBs were coinjected with MBs into NIH/3T3 cells.
Despite the presence of a competitive inhibitor, we
continued to observe an increase in MB ﬂuorescence in
Figure 1. Intracellular ﬂuorescence of MBs and NeutrAvidin–MB conjugates. (a) Fluorescent microscopy images of NIH/3T3 cells injected with
20-O-methyl RNA MBs. The MBs were not perfectly complementary to any known endogenous RNA in mice. (b) NIH/3T3 cells were injected with
MB–NeutrAvidin conjugates. NeutrAvidin was labeled with the ﬂuorescent dye, Alexa750, to facilitate imaging of their intracellular distribution.
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responsible for the false-positive signals.
Previously, we and others have demonstrated that by
linking MBs to macromolecules such as quantum dots
or streptavidin they can be eﬀectively retained in the
cytoplasm (2,5). In the present study, we conjugated 20-O-
methyl RNA MBs to ﬂuorescently labeled NeutrAvidins
to prevent nuclear sequestration. Immediately following
cytoplasmic injection, ﬂuorescent signals from both the
MBs and NeutrAvidins were only observed in the cyto-
plasm of the cells (Figure 1b). While NeutrAvidin signals
were clearly distinguished from the background, the MB
ﬂuorescence signal was extremely faint and barely
detectable above the background. Thirty minutes after
the injection, the total MB ﬂuorescence within the entire
cell increased by only  6%. This small increase in signal
likely results from a small amount of unbound MB that
localized to the nucleus (i.e. a faint ﬂuorescent signal was
observed in the nucleus). As a result, conjugation of
NeutrAvidins to MBs not only helps overcome nuclear
sequestration of the MBs, but also eﬀectively prevents the
generation of false-positive signals.
NeutrAvidin conjugates aredirected towardslysosomes
when TAT-peptide, SLO or microporation areused
forintracellular delivery
To investigate whether TAT peptides can be used to
deliver NeutrAvidin conjugates into the cytosol of living
cells, NIH/3T3 cells were treated with Cy5-labeled
NeutrAvidins conjugated to TAT peptides and imaged
at various time points. Shortly after the addition of the
TAT–NeutrAvidin conjugates a uniform ﬂuorescent
signal could be observed on the surface of the cells. By
4h, punctate ﬂuorescent staining could be observed within
the cytoplasm of the cells, while no ﬂuorescence was
observed in the nucleus. Similar patterns persisted over
the course of 24h (Figure 2a). Live-cell staining with the
lysosomal labeling dye, LysoTracker, indicated that the
Figure 2. Delivery of NeutrAvidin conjugates into single living cells. Cy5-labeled NeutrAvidins were delivered into NIH/3T3 cells either by
(a) TAT-peptide, (b) SLO or (c) microporation. Images corresponding to TAT-peptide-based delivery and microporation were acquired 24h
following delivery. Images corresponding to delivery via SLO were acquired immediately after the permeabilized membranes were resealed,  1.5h.
Subsequent staining of the cells with LysoTracker was used to determine whether the pegylated NeutrAvidin was localized within lysosomes for each
of the delivery methods, (d) TAT-peptide, (e) SLO and (f) microporation. The merged NeutrAvidin and lysosome images for (g) TAT peptide,
(h) SLO, and (i) microporation show all colocalized ﬂuorescent signals as yellow in color. The contrast in the yellow channel of the merged images
was increased to more clearly distinguish areas of colocalization from the pure red and green signals.
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were localized in lysosomes (Figure 2d). We further
explored the possibility of enhancing endosomal release
of TAT-NeutrAvidins by employing pH-sensitive fuso-
genic peptides, i.e. INF-7, GALA-INF3 and HA2. These
fusogenic peptides have previously been reported to
disrupt endosomes, causing them to release their contents
(40,41). When NIH/3T3 cells were co-incubated with
TAT–NeutrAvidin and various concentrations of each
of the fusogenic peptides, a punctate ﬂuorescent staining
pattern was still observed in the cytoplasms. This signal
was largely colocalized with the lysosomal labeling dye,
LysoTracker (data not shown). It should be noted that
these results do not completely rule out the possibility
that some endosomes were disrupted by the fusogenic
peptides. For example, it is possible that the cytoplasmic
signal was too weak to be observed relative to the bright
ﬂuorescent signal emanating from the lysosomes; how-
ever, it does appear that endosomal disruption is ineﬃ-
cient. Therefore, based on our observations, TAT peptides
are not eﬀective in delivering ﬂuorescently labeled
NeutrAvidin conjugates into the cytosol of living cells.
To investigate whether SLO could be used to eﬃciently
deliver NeutrAvidin conjugates into the cytosol of living
cells, NIH/3T3 cells were treated with SLO and varying
amounts of ﬂuorescently labeled NeutrAvidins (0.8, 2.3,
3.6 and 6.25mM). Immediately after the permeabilized
membranes were resealed, intracellular ﬂuorescent signals
were detectable but only when relatively high concentra-
tions of NeutrAvidin were utilized (>3mM) (Figure 2b).
Furthermore, there was a large cell-to-cell variation in
total cellular ﬂuorescence, and also variability in the
intracellular pattern of ﬂuorescence. Speciﬁcally, some
cells appeared to exhibit ﬂuorescent signals throughout
the entire cell, including both cytoplasm and the nucleus,
while other cells exhibited a more punctate pattern. After
24h, nearly all of the cells exhibited a punctate ﬂuorescent
pattern (data not shown). Colocalization of the punctate
ﬂuorescent signals with the LysoTracker dye conﬁrmed
that the majority of the NeutrAvidins were localized in
lysosomes.
To investigate whether microporation could be used to
eﬃciently deliver NeutrAvidin into the cytosol of living
cells, 3mM of Cy5-labeled NeutrAvidins were micropo-
rated into NIH/3T3 cells. Bright ﬂuorescent signals were
observed in the cells immediately following micropora-
tion, while the cells were still in suspension; however, after
24h the ﬂuorescent signal became punctate (Figure 2c).
Colocalization of the NeutrAvidin signal with the
LysoTracker dye indicated that the NeutrAvidins were
localized in lysosomes (Figure 2f).
In order to identify whether the Cy5 dye was
responsible for targeting the Cy5–NeutrAvidin conjugates
to lysosomes, we delivered just the Cy5 dye into living cells
via SLO and microporation. In both cases, the dye was
initially diﬀused throughout the cell, but over time the
ﬂuorescent signal in the cytoplasm dissipated suggesting
leakage of the dye from the cytoplasmic compartment.
After 24h there was still some signal remaining in the
lysosomes, but the ﬂuorescent signal was extremely faint.
Based on these ﬁndings, we do not believe that Cy5
targeted the NeutrAvidin to lysosomes. To further
conﬁrm this point, we also delivered Alexa750-labeled
NeutrAvidin into cells via SLO and microporation. In
each case, we observed similar intracellular localization as
with Cy5–NeutrAvidin. This suggests that the ﬂuorescent
label is not responsible for targeting NeutrAvidin to
lysosomes.
Pegylation improves cytosolic delivery of NeutrAvidin
conjugates by microporation
Considering the uniform distribution of ﬂuorescently
labeled NeutrAvidin observed following microinjection, it
was surprising to ﬁnd that CPPs, SLO and microporation
all resulted in punctate ﬂuorescent staining. In particular,
both SLO and microporation directly porate the cellular
membrane and will allow direct passage of extracellular
proteins into the cytoplasm. In response to these puzzling
results, we hypothesized that coating the ﬂuorescently
labeled NeutrAvidin with polyethylene glycol (PEG) may
improve cytosolic delivery. PEG coatings are commonly
used to improve solubility, diminish the potential for
aggregation, improve biocompatibility, and minimize
nonspeciﬁc interactions.
When pegylated NeutrAvidin conjugates were deliv-
ered into the cells by TAT peptide, a punctate ﬂuo-
rescent pattern was again observed in the cytoplasm
of NIH/3T3 cells (Figure 3a). Colocalization of the
NeutrAvidin-signal with the LysoTracker dye again indi-
cated that the majority of the proteins were localized
in the lysosomes (Figure 3d). Therefore, pegylation
did not seem to improve the cytosolic delivery of
NeutrAvidin, as the majority of the probes were still loca-
lized in lysosomes. Overall, we conclude that TAT
peptides can eﬀectively be used to internalize macromo-
lecules into cells, but these macromolecules predominantly
reside in lysosomes.
Pegylated NeutrAvidins were also delivered into the
cells by SLO (Figure 3b). Again, pegylation did not seem
to signiﬁcantly improve the cytosolic delivery of ﬂuores-
cently labeled NeutrAvidin. Speciﬁcally, immediately after
the permeabilized membranes were resealed, a few cells
appeared to exhibit ﬂuorescent signals throughout the
cell but most cells exhibited punctate ﬂuorescent signals.
Furthermore, there was still a large cell-to-cell variation in
ﬂuorescence between cells. After 24h, nearly all of the
cells exhibited a punctate ﬂuorescent pattern (data not
shown). Colocalization of the punctate ﬂuorescent
signals with the LysoTracker signal conﬁrmed that the
majority of the NeutrAvidins were localized in the
lysosomes.
Finally, when microporation experiments were per-
formed with pegylated NeutrAvidin conjugates, the
majority of the ﬂuorescent signal was observed in the
cytoplasm of NIH/3T3 cells (Figure 3c). There were still a
small number of bright ﬂuorescent spots within each cell,
but otherwise the intracellular distribution closely
resembled that of NeutrAvidin following microinjection.
The diﬀuse ﬂuorescent signal persisted in the cytoplasm
for at least 24h. This could be beneﬁcial for temporal
measurements of gene expression in living cells.
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intracellular distribution of NeutrAvidin conjugates,
another exciting beneﬁt of using microporation for
delivery is the small amount of sample needed. Only
10mlo f3 mM sample was needed per 100000 cells
compared with 175ml of 3.6mM sample for SLO. This is
an important beneﬁt when only a limited amount of
sample is available.
Microporation offers highcell viability and transfection
efficiency
In general, electroporation is often considered an invasive
procedure that results in poor viability. To speciﬁcally test
the eﬀect of ‘microporation’ on cell viability, an MTT cell
proliferation assay was performed on cells that were
microporated using various voltages and probe concentra-
tions. In general, viability decreased as the microporation
voltage was increased (Figure 4a). Speciﬁcally, the viability
was 86 5%, 78 11% and 66 10% (n=3) for 1250,
1500 and 1740V, respectively. Increasing the con-
centration of the pegylated NeutrAvidin conjugates from
0t o3mM did not seem to have any signiﬁcant eﬀect on cell
viability (one-way ANOVA, F=0.245, P=0.79) (data
not shown).
To determine the eﬀect of voltage on transfection
eﬃciency, cells were microporated with 3mM of ﬂuores-
cently labeled and pegylated NeutrAvidin at 0, 1250, 1500
and 1740V before being analyzed by ﬂow cytometry. It
was found that the transfection eﬃciency increased with
increasing voltage settings (Figure 4b). Speciﬁcally,
transfection eﬃciencies at 1250, 1500 and 1740V were
Figure 3. Delivery of pegylated NeutrAvidin into single living cells. Cy5-labeled NeutrAvidins colabeled with PEG were delivered into NIH/3T3 cells
either by (a) TAT peptide, (b) SLO or (c) microporation. Images corresponding to TAT-peptide-based delivery and microporation were acquired 24h
following delivery. Images corresponding to delivery via SLO were acquired immediately after the permeabilized membranes were resealed,  1.5h.
Subsequent staining of the cells with LysoTracker was used to determine whether the pegylated NeutrAvidin was localized within lysosomes for each
of the delivery methods, (d) TAT-peptide, (e) SLO, and (f) microporation. The merged NeutrAvidin and lysosme images for (g) TAT peptide,
(h) SLO and (i) microporation show all colocalized ﬂuorescent signals as yellow in color. The contrast in the yellow channel of the merged images
was increased to more clearly distinguish areas of colocalization from the pure red and green signals.
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microporation itself (at 1740V) does not aﬀect cell
autoﬂuorescence. Overall, microporation appears to
yield a high transfection eﬃciency of the NeutrAvidin
conjugates. These results, combined with the high viability
of NIH/3T3 cells after microporation, particularly at
1250V, suggest that microporation provides a viable
approach for the high-throughput delivery of MB–
NeutrAvidin conjugates into living cells.
To evaluate the eﬀect of probe concentration on
transfection eﬃciency, cells were microporated with
diﬀerent concentrations of pegylated NeutrAvidin con-
jugates before being analyzed by ﬂow cytometry
(Figure 5). As expected, the average ﬂuorescent signal
per cell and the percentage of transfected cells increased as
the concentration of NeutrAvidin was increased.
Speciﬁcally,  93% of the cells exhibited a distinct
ﬂuorescent signal when microporated with 1mMo f
NeutrAvidin and  96% of the cells exhibited a distinct
ﬂuorescent signal when microporated with 3mMo f
NeutrAvidin. Our results are consistent with the general
notion that higher voltage settings and higher extracellular
protein concentrations can both lead to improved cyto-
solic delivery of proteins when applying electroporation.
Flow cytometric analysis ofRNAs in single livingcells
In order to evaluate whether pegylated NeutrAvidin–MB
conjugates could be used to detect gene expression in
single living cells, microporation experiments were per-
formed using antisense luciferase 2-O0-methyl RNA MB
conjugates. Speciﬁcally, MB–NeutrAvidin conjugates
were microporated into NIH/3T3 cells that express the
luciferase protein (luc+). Two negative control experi-
ments were conducted to examine whether the measured
ﬂuorescent signal reﬂected MB hybridization or false-
positive events. The ﬁrst control experiment consisted of
microporating MB–NeutrAvidin conjugates into NIH/
3T3 cells that do not express luciferase (luc ). The second
negative control consisted of microporating luc+ cells in
the absence of MB–NeutrAvidin conjugates (i.e. no
probe). This experiment was performed to determine the
level of cellular autoﬂuorescence. A positive control
experiment was also conducted to determine the max-
imum attainable signal in the cells. This experiment
consisted of microporating MB conjugates prehybridized
to synthetic luciferase RNA targets into the luc+ cells.
Representative ﬂow cytometry results are shown in
Figure 6a. In order to calculate the signal-to-background
(S:B) of the MB–NeutrAvidin conjugates, ﬁrst the mean
ﬂuorescent signal of cells microporated in the absence of
probe (i.e. autoﬂuorescence) was subtracted from the
Figure 4. The eﬀect of microporation voltage settings on cell viability and transfection eﬃciency. (a) NIH/3T3 cells were microporated in the
presence of 3mM FITC-labeled, pegylated NeutrAvidins at 0, 1250, 1500 or 1740V. The corresponding viability was determined by MTT assay.
Viability was determined relative to cells that were not microporated (0V). (b) Flow cytometry histograms for NIH/3T3 cells microporated at
diﬀerent voltage levels 0V (brown), 1250V (blue), 1500V (green) and 1740V (red).
Figure 5. The eﬀect of probe concentration on transfection eﬃciency.
NIH/3T3 cells were microporated in the presence of 0mM (brown),
1mM (blue), 2mM (green) and 3mM (red) of FITC-labeled and
pegylated NeutrAvidin at 1740V before being analyzed by ﬂow
cytometry.
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luc+ cells microporated with prehybridized MB–
NeutrAvidin conjugates was divided by the mean ﬂuor-
escent signal of luc  cells microporated with MB–
NeutrAvidin conjugates, giving an S:B of 6.7. When
MB–NeutrAvidin conjugates were microporated into
Luc+ cells, the mean ﬂuorescent signal was calculated
to be 182% higher than luc  cells microporated with MB–
NeutrAvidin conjugates.
To highlight the importance of designing MBs that are
not sequestered into the nucleus, analogous ﬂow cytome-
try experiments were conducted with NIH/3T3 cells that
were microporated with unconjugated antisense 20-O-
methyl RNA MBs (i.e. not conjugated to NeutrAvidin)
(Figure 6b). It was found that unconjugated MBs exhibit
signiﬁcantly higher background ﬂuorescence in Luc  cells
compared with cells microporated with the MB–
NeutrAvidin conjugates. Speciﬁcally, the S:B of cells
microporated with unconjugated MBs was calculated to
be only 2.15. This S:B is more than three times lower than
the S:B achieved with MB–NeutrAvidin conjugates. The
low S:B observed with unconjugated MBs likely stems
from the high background signal present in the nucleus
(Figure 1a). This high background also has a signiﬁcant
negative eﬀect on the MB’s ability to sensitively detect
RNA. Speciﬁcally, when unconjugated MBs were micro-
porated into Luc+ cells, the mean ﬂuorescent signal was
calculated to be only 37% higher than luc  cells
microporated with unconjugated MBs. Therefore, the
sensitivity for detecting luciferase RNA targets was nearly
ﬁve times lower than with MB–NeutrAvidin conjugates.
These results clearly highlight the advantages of retaining
MBs in the cytoplasm for accurate RNA detection and
may present an opportunity for quantiﬁcation of RNA in
living cells.
In summary, we demonstrate that MBs composed of
20-O-methyl RNA backbones only elicit a nonspeciﬁc
signal in the nucleus. When MBs are retained in the
cytoplasmic compartment, by conjugation to
NeutrAvidins, false-positive signals are reduced to mar-
ginal levels. Delivery of these MB–NeutrAvidin conju-
gates can be achieved by microporation, which allows for
high transfection eﬃciency and high viability. Utilizing
ﬂow cytometry for high-throughput analysis of gene
expression, MB–NeutrAvidin conjugates allowed for a
higher sensitivity and improved dynamic range in RNA
detection compared with conventional MBs. As a result,
MB–NeutrAvidin conjugates can be used as an eﬀective
tool for detecting the expression of speciﬁc RNAs in living
cells.
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